Cargando…
Critical analysis of the use of β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer’s disease
Alzheimer’s disease (AD) is the major cause of dementia in the elderly and an unmet clinical challenge. A variety of therapies that are currently under development are directed to the amyloid cascade. Indeed, the accumulation and toxicity of amyloid-β (Aβ) is believed to play a central role in the e...
Autores principales: | Evin, Genevieve, Barakat, Adel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337240/ https://www.ncbi.nlm.nih.gov/pubmed/32669897 http://dx.doi.org/10.2147/DNND.S41056 |
Ejemplares similares
-
Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2
por: Yan, Riqiang
Publicado: (2017) -
Withdrawal: Ceramide stabilizes β-site amyloid precursor
protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis
por: Puglielli, Luigi, et al.
Publicado: (2022) -
β-site amyloid precursor protein-cleaving
enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid
precursor protein cleavage
por: Portelius, Erik, et al.
Publicado: (2014) -
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer’s disease patients
por: Kirsebom, Bjørn Eivind, et al.
Publicado: (2022) -
Arylbenzofurans from the Root Bark of Morus alba as Triple Inhibitors of Cholinesterase,
β-Site Amyloid Precursor Protein Cleaving Enzyme 1, and
Glycogen Synthase Kinase-3β: Relevance to Alzheimer’s
Disease
por: Paudel, Pradeep, et al.
Publicado: (2019)